EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutationsMichael T. McCabe, Caretha L. Creasy, Martín Brandt et al.|Nature|2012Cited by 1.8k
BET Inhibition Silences Expression of MYCN and BCL2 and Induces Cytotoxicity in Neuroblastoma Tumor ModelsAnastasia Wyce, Peter J. Tummino, Gopinath Ganji et al.|PLoS ONE|2013Cited by 205
Inhibition of BET bromodomain proteins as a therapeutic approach in prostate cancerAnastasia Wyce, Olena Barbash, Yan Degenhardt et al.|Oncotarget|2013Cited by 179
MEK inhibitors overcome resistance to BET inhibition across a number of solid and hematologic cancersAnastasia Wyce, Olena Barbash, Jeanne J. Matteo et al.|Oncogenesis|2018Cited by 36
Abstract 4700: A novel selective EZH2 inhibitor exhibits anti-tumor activity in lymphoma with EZH2 activating mutationsCaretha L. Creasy, Peter J. Tummino, Michael T. McCabe et al.|Cancer Research|2012Cited by 3